Literature DB >> 1460210

The anticholinergic treatment of allergic perennial rhinitis.

J W Georgitis1.   

Abstract

Anticholinergic agents have been used for nonallergic rhinitis expressly to control rhinorrhea. In allergic rhinitis, rhinorrhea can be extremely troublesome and unresponsive to traditional pharmacotherapeutic rhinitis treatments. Anticholinergic agents, through their specific ability to decrease nasal secretory response, should have beneficial effects for allergic rhinitis. In a recent trial ipratropium bromide at concentrations of 0.03% and 0.06% reduced rhinorrhea in allergic subjects without any demonstrable rebound effect. Therefore anticholinergic therapies may be a useful adjunct in controlling the rhinorrhea associated with allergic rhinitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1460210     DOI: 10.1016/0091-6749(92)90125-l

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.

Authors:  Gregory D Scott; Allison D Fryer
Journal:  Chem Immunol Allergy       Date:  2012-06-26

Review 2.  Intranasal steroids in the treatment of allergy-induced rhinorrhea.

Authors:  Robert A Nathan
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

3.  Cholinergic Synapse Pathway Gene Polymorphisms Associated With Late-Phase Responses in Allergic Rhinitis.

Authors:  Simranjit K Samra; Ashwini Rajasekaran; Andrew J Sandford; Anne K Ellis; Scott J Tebbutt
Journal:  Front Allergy       Date:  2021-08-16

4.  Taurine promotes the production of CD4+CD25+FOXP3+ Treg cells through regulating IL-35/STAT1 pathway in a mouse allergic rhinitis model.

Authors:  Jing Zhou; Yi Lu; Wei Wu; Yunhai Feng
Journal:  Allergy Asthma Clin Immunol       Date:  2021-06-19       Impact factor: 3.406

5.  Anticholinergic drugs in nonallergic rhinitis.

Authors:  Robert Naclerio
Journal:  World Allergy Organ J       Date:  2009-08-15       Impact factor: 4.084

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.